- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Summer 2017
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Altaire Pharms., Inc. v. Paragon Bioteck, Inc., 17-1837 (E.D.N.Y.) | Mar. 31, 2017 | Hon. William F. Kuntz, II | phenylephrine HCl ophthalmic solution | 8,859,623 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-0365 (D. Del.) | Apr. 3, 2017 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 6,992,218 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-1521 (E.D. Pa.) | Apr. 4, 2017 | Hon. Jeffrey L. Schmehl | Ofirmev® (acetaminophen for injection) | 9,399,012 6,992,218 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01100 (PTAB) | Apr. 4, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,853,260 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01101 (PTAB) | Apr. 4, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,820,788 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01103 (PTAB) | Apr. 4, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,923,536 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01104 (PTAB) | Apr. 4, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,138,229 |
| Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., 17-0374 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Breckenridge Pharm., Inc., 17-0375 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Hetero USA Inc., 17-0376 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Invagen Pharms., Inc., 17-0377 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Lupin Ltd., 17-0378 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Mylan Pharms. Inc., 17-0379 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sunshine Lake Pharma Co., Ltd., 17-0380 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Torrent Pharms. Ltd., 17-0381 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Unichem Labs., Ltd., 17-0382 (D. Del.) | Apr. 5, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Gilead Sciences, Inc. v. Amneal Pharms., LLC, 17-2335 (D.N.J.) | Apr. 6, 2017 | Hon. Michael A. Shipp | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 8,716,264 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 17-0389 (D. Del.) | Apr. 7, 2017 | Hon. Richard G. Andrews | Afinitor Disperz® (everolimus tablets) | 5,665,772 8,778,962 8,617,598 |
| Purdue Pharma L.P. v. Intellipharmaceutics Int’l Inc., 17-0392 (D. Del.) | Apr. 7, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,492,389 9,492,391 8,309,060 |
| Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 17-0393 (D. Del.) | Apr. 7, 2017 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 9,006,224 8,410,131 8,778,962 8,436,010 |
| Dexcel Pharma Technologies Ltd. v. Apotex Corp., 17-2423 (D.N.J.) | Apr. 7, 2017 | Hon. Susan D. Wigenton | omeprazole delayed-release tablets | 9,023,391 7,255,878 |
| Shire-NPS Pharms., Inc. v. Ambio, Inc., 17-0397 (D. Del.) | Apr. 10, 2017 | Hon. Gregory M. Sleet | Gattex® (teduglutide for Injection) | 7,056,886 7,847,061 9,060,992 |
| Bristol-Myers Squibb Co. v. Accord Healthcare Inc., 17-0398 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Apotex, Inc., 17-0399 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 6,413,980 |
| Bristol-Myers Squibb Co. v. Bionpharma Inc., 17-0400 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Dr. Reddy’s Labs., Ltd., 17-0401 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Emcure Pharms. Ltd., 17-0402 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Impax Labs., Inc., 17-0403 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Indoco Remedies Ltd., 17-0404 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Macleods Pharms. Ltd., 17-0405 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Micro Labs USA Inc., 17-0406 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sandoz Inc., 17-0407 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sigmapharm Labs., LLC, 17-0408 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sun Pharm. Indus. Inc., 17-0409 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 17-0410 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Wockhardt Bio AG, 17-0411 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. Zydus Pharms. (USA) Inc., 17-0412 (D. Del.) | Apr. 10, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc., 17-2448 (D.N.J.) | Apr. 10, 2017 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Jazz Pharms., Inc. v. Amneal Pharms. LLC, 17-2452 (D.N.J.) | Apr. 10, 2017 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,539,330 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 17-0054 (N.D.W.V.) | Apr. 10, 2017 | Hon. Irene M. Keeley | Afinitor Disperz® (everolimus tablets) | 5,665,772 8,778,962 8,617,598 |
| Celgene Corp. v. Zydus Pharms. (USA) Inc., 17-2528 (D.N.J.) | Apr. 12, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
| Bristol-Myers Squibb Co. v. Mylan Pharms. Inc., 17-0055 (N.D.W.V.) | Apr. 12, 2017 | Hon. Irene M. Keeley | Eliquis® (apixaban tablets) | 6,967,208 9,326,945 |
| Novartis Pharms. Corp. v. Breckenridge Pharm., Inc., 17-0420 (D. Del.) | Apr. 13, 2017 | Hon. Richard G. Andrews | Affinitor® (everolimus tablets) | 5,665,772 8,410,131 8,778,962 |
| Millennium Pharms., Inc. v. Amneal Pharms. LLC, 17-0422 (D. Del.) | Apr. 13, 2017 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446 6,958,319 |
| Millennium Pharms., Inc. v. Zydus Pharms. (USA) Inc., 17-0423 (D. Del.) | Apr. 13, 2017 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) | 6,713,446 6,958,319 |
| Bristol-Myers Squibb Co. v. Prinston Pharm. Inc., 17-0426 (D. Del.) | Apr. 13, 2017 | Hon. Leonard P. Stark | Eliquis® (apixaban tablets) | 9,326,945 |
| Eli Lilly and Co. v. Dr. Reddy’s Labs., Inc., 17-2541 (D.N.J.) | Apr. 13, 2017 | Hon. Kevin McNulty | Cialis® (tadalafil tablets) | 6,943,166 |
| Sucampo AG v. Amneal Pharms. LLC, 17-2577 (D.N.J.) | Apr. 13, 2017 | Hon. Peter G. Sheridan | Amitiza® (lubiprostone capsules) | 6,982,283 8,097,653 8,389,542 8,026,393 8,338,639 |
| Eli Lilly and Co. v. Par Pharm., Inc., 17-1219 (S.D. Ind.) | Apr. 18, 2017 | Hon. William T. Lawrence | Axiron® (testosterone metered transdermal solution) | 8,435,944 8,993,520 9,180,194 8,419,307 8,177,449 8,807,861 9,289,586 |
| AstraZeneca Pharms. LP v. HBT Labs., Inc., 17-2652 (D.N.J.) | Apr. 18, 2017 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Par Pharm., Inc. v. Sumitomo Dainippon Pharma Co., Ltd., IPR2017-01292 (PTAB) | Apr. 18, 2017 | N/A | Latuda® (lurasidone hydrochloride tablets) | 9,555,027 |
| Ferring Pharms. Inc. v. Teva Pharms. USA, Inc., 17-0435 (D. Del.) | Apr. 19, 2017 | Hon. Richard G. Andrews | Prepopik® (sodium picosulfate / magnesium oxide / citric acid oral solution) | 8,450,338 8,481,083 |
| Meda Pharms. Inc. v. Akorn, Inc., 17-0439 (D. Del.) | Apr. 19, 2017 | Hon. Gregory M. Sleet | Astepro® (azelastine HCl nasal spray) | 8,071,073 8,518,919 |
| Onyx Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-0449 (D. Del.) | Apr. 20, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,232,818 7,491,704 7,737,112 8,129,346 8,207,125 8,207,126 8,207,127 8,207,297 |
| Purdue Pharma L.P. v. Abhai, LLC, 17-0450 (D. Del.) | Apr. 20, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,492,389 9,492,391 9,492,392 9,492,393 9,522,919 |
| Amneal Pharms. LLC v. Pfizer Inc., 17-0454 (D. Del.) | Apr. 20, 2017 | Vacant Judgeship (2017) | Zithromax® (azithromycin oral suspension) | 6,268,489 |
| Eli Lilly and Co. v. Par Pharm., Inc., 17-0456 (D. Del.) | Apr. 21, 2017 | Hon. Leonard P. Stark | Axiron® (testosterone metered transdermal solution) | 8,435,944 8,993,520 9,180,194 8,419,307 8,177,449 8,807,861 9,289,586 |
| Bayer Intellectual Property GMBH v. Taro Pharm. Indus. Ltd., 17-0462 (D. Del.) | Apr. 21, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Purdue Pharms. LP v. Collegium Pharm., Inc., 17-10690 (D. Mass.) | Apr. 21, 2017 | Hon. F. Dennis Saylor, IV | OxyContin® (oxycodone HCl extended-release tablets) | 9,522,919 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 17-2754 (D.N.J.) | Apr. 21, 2017 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,359,302 |
| Allergan Sales, LLC v. Teva Pharms. USA, Inc., 17-0343 (E.D. Tex.) | Apr. 21, 2017 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Galderma Labs., L.P. v. Actavis Labs UT, Inc., 17-1076 (N.D. Tex.) | Apr. 21, 2017 | Hon. Barbara M.G. Lynn | Soolantra® (ivermectin cream) | 8,362,069 8,815,816 9,089,587 9,233,117 9,233,118 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 17-2877 (D.N.J.) | Apr. 26, 2017 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,561,177 |
| Ferring Pharms. Inc. v. Serenity Pharms., LLC, 17-0479 (D. Del.) | Apr. 28, 2017 | Hon. Gregory M. Sleet | Noctiva® (desmopressin acetate nasal spray) | 7,405,203 7,579,321 7,799,761 |
| Bayer Intellectual Property GMBH v. Aurobindo Pharma Ltd., 17-0483 (D. Del.) | Apr. 28, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Celgene Corp. v. Par Pharm., Inc., 17-3159 (D.N.J.) | 4-May-17 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Helsinn Healthcare S.A. v. Virtus Pharms., LLC, 17-3216 (D.N.J.) | 4-May-17 | Hon. Mary L. Cooper | Aloxi® (palonosetron HCl for injection) | 7,947,724 7,947,725 7,960,424 8,598,219 8,729,094 |
| Depomed, Inc. v. Strides Pharma, Inc., 17-3180 (D.N.J.) | 5-May-17 | Hon. Jose L. Linares | Zipsor® (diclofenac potassium capsules) | 7,662,858 7,884,095 7,939,518 8,110,606 8,623,920 9,561,200 |
| Takeda Pharm. Co. Ltd. v. Torrent Pharms. Ltd., 17-3186 (D.N.J.) | 5-May-17 | Hon. Stanley R. Chesler | Nesina® (alogliptin benzoate tablets) Oseni® (alogliptin benzoate / pioglitazone HCl tablets) Kazano® (alogliptin benzoate / metformin HCl tablets) | 7,807,689 8,173,663 8,288,539 8,900,638 |
| Rhodes Pharms. L.P. v. Ascent Pharms. Inc., 17-2755 (E.D.N.Y.) | 5-May-17 | Hon. Pamela K. Chen | Dilaudid® (hydromorphone HCl oral solution) | 6,589,960 |
| Astellas Pharma Inc. v. Roxane Labs., Inc., 17-0542 (D. Del.) | 9-May-17 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517 8,183,274 9,126,941 |
| Impax Labs., Inc. v. Actavis Labs. FL, Inc., 17-3295 (D.N.J.) | 9-May-17 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa capsules) | 9,533,046 |
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 17-3342 (D.N.J.) | 11-May-17 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,539,335 |
| Celgene Corp. v. Hetero Labs Ltd., 17-3387 (D.N.J.) | 11-May-17 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Novo Nordisk Inc. v. Glenmark Pharms. Ltd., 17-3462 (D.N.J.) | 11-May-17 | Hon. Michael A. Shipp | Vagifem® (estradiol vaginal tablets) | 7,018,992 |
| Bayer Intellectual Property GMBH v. Micro Labs Ltd., 17-0560 (D. Del.) | 12-May-17 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Argentum Pharms. LLC v. Kaken Pharm. Co., Ltd., IPR2017-01429 (PTAB) | 12-May-17 | N/A | Jublia® (efinaconazole topical solution) | 7,214,506 |
| Micro Labs Ltd. v. Santen Pharm. Co., Ltd., IPR2017-01434 (PTAB) | 12-May-17 | N/A | Zioptan® (tafluprost ophthalmic solution) | 5,886,035 |
| Taro Pharms. U.S.A., Inc. v. Apotex Technologies, Inc., IPR2017-01446 (PTAB) | 17-May-17 | N/A | Ferriprox® (deferiprone oral solution/tablets) | 7,049,328 |
| Bayer Intellectual Property GMBH v. Mylan Pharms. Inc., 17-0584 (D. Del.) | 19-May-17 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Genzyme Corp. v. Ingenus Pharms. LLC, 17-0602 (D. Del.) | 24-May-17 | Hon. Leonard P. Stark | Clolar® (clofarabine for injection) | 5,661,136 |
| Acorda Therapeutics, Inc. v. Micro Labs Ltd., 17-3724 (D.N.J.) | 24-May-17 | Hon. Brian R. Martinotti | Ampyra® (dalfampridine extended-release tablets) | 8,007,826 8,354,437 8,440,703 8,663,685 |
| Bayer Intellectual Property GMBH v. Sigmapharm Labs., LLC, 17-0648 (D. Del.) | 26-May-17 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Upsher-Smith Labs., Inc. v. Glenmark Pharms. Ltd., 17-0649 (D. Del.) | 26-May-17 | Vacant Judgeship (2017) | Qudexy® XR (topiramate extended-release capsules) | 8,652,527 8,889,190 9,101,545 9,555,005 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-0660 (D. Del.) | 31-May-17 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 |
| Allergan Inc. v. Taro Pharm. Industries Ltd., 17-0663 (D. Del.) | 1-Jun-17 | Vacant Judgeship (2017) | Aczone® (dapsone gel) | 9,517,219 |
| Osi Pharms., LLC v. Hetero USA Inc., 17-0665 (D. Del.) | 1-Jun-17 | Hon. Gregory M. Sleet | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Osi Pharms., LLC v. Sun Pharms. Industries Inc., 17-0666 (D. Del.) | 1-Jun-17 | Hon. Gregory M. Sleet | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Forest Labs., LLC v. Macleods Pharms., Ltd., 17-0672 (D. Del.) | 2-Jun-17 | Hon. Leonard P. Stark | Namenda XR® (memantine HCl extended-release capsules) | 8,039,009 8,168,209 8,173,708 8,283,379 |
| Forest Labs., LLC v. Macleods Pharms., Ltd., 17-0673 (D. Del.) | 2-Jun-17 | Hon. Leonard P. Stark | Namzaric® (memantine HCl / donepezil HCl extended-release capsules) | 8,039,009 8,058,291 8,338,485 8,338,486 8,580,858 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-2474 (E.D. Pa.) | 2-Jun-17 | Hon. Jeffrey L. Schmehl | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-0677 (D. Del.) | 5-Jun-17 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) | 9,486,412 9,486,413 9,492,389 9,492,390 9,492,391 9,545,380 9,517,236 9,572,779 9,572,804 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01526 (PTAB) | 5-Jun-17 | N/A | Lantus® (insulin glargine recombinant for injection) | 7,476,652 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01528 (PTAB) | 5-Jun-17 | N/A | Lantus® (insulin glargine recombinant for injection) | 7,713,930 |
| Pfizer Inc. v. Macleods Pharms., Ltd., 17-0683 (D. Del.) | 6-Jun-17 | Hon. Richard G. Andrews | Viagra® (sildenafil citrate tablets) | 6,469,012 |
| Amgen Inc. v. Piramal Healthcare UK Ltd., 17-0713 (D. Del.) | 9-Jun-17 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| AstraZeneca LP v. Apotex Inc., 17-0714 (D. Del.) | 9-Jun-17 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | RE46,276 7,250,419 7,265,124 |
| Argentum Pharms. LLC v. Novartis A.G., IPR2017-01550 (PTAB) | 9-Jun-17 | N/A | Gilenya® (fingolimod capsules) | 9,187,405 |
| Par Pharm., Inc. v. MonoSol Rx, LLC, IPR2017-01557 (PTAB) | 9-Jun-17 | N/A | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 8,603,514 |
| Noden Pharma DAC v. Anchen Pharms., Inc., 17-0728 (D. Del.) | 12-Jun-17 | Vacant Judgeship (2017) | Tekturna® (aliskiren hemifumarate tablets) | 8,617,595 |
| Kowa Co., Ltd. v. Hetero Drugs Ltd., 17-4421 (S.D.N.Y.) | 12-Jun-17 | Hon. Paul A. Crotty | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Dr. Reddy’s Labs. S.A. v. MonoSol Rx, LLC, IPR2017-01582 (PTAB) | 12-Jun-17 | N/A | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 8,603,514 |
| Breckenridge Pharm., Inc. v. Novartis Pharms. Corp., IPR2017-01592 (PTAB) | 12-Jun-17 | N/A | Afinitor® (everolimus tablets) | 8,410,131 |
| Orexo AB v. Actavis Elizabeth LLC, 17-0758 (D. Del.) | 14-Jun-17 | Hon. Gregory M. Sleet | Zubsolv® (buprenorphine HCl / naloxone HCl dehydrate sublingual tablets) | 9,259,421 8,940,330 |
| Kowa Co., Ltd. v. Hetero Drugs Ltd., 17-0762 (D. Del.) | 14-Jun-17 | Hon. Gregory M. Sleet | Livalo® (pitavastatin calcium tablets) | 8,557,993 |
| Cosmo Technologies Ltd. v. Sun Pharm. Industries, Ltd., 17-4393 (D.N.J.) | 15-Jun-17 | Hon. Peter G. Sheridan | Uceris® (budesonide extended-release tablets) | 9,320,716 |
| Belcher Pharms., LLC v. Hospira, Inc., 17-0775 (D. Del.) | 19-Jun-17 | Hon. Leonard P. Stark | Abboject® (epinephrine for injection) | 9,283,197 |
| Omeros Corp. v. Sandoz Inc., 17-0799 (D. Del.) | 21-Jun-17 | Hon. Richard G. Andrews | Omidria® (phenylephrine / ketorolac for injection) | 8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Omeros Corp. v. Sandoz Inc., 17-4564 (D.N.J.) | 21-Jun-17 | Hon. Brian R. Martinotti | Omidria® (phenylephrine / ketorolac for injection) | 8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Watson Labs., Inc. v. United Therapeutics, Inc., IPR2017-01621 (PTAB) | 21-Jun-17 | N/A | Tyvaso® (treprostinil solution for inhalation) | 9,358,240 |
| Watson Labs., Inc. v. United Therapeutics, Inc., IPR2017-01622 (PTAB) | 21-Jun-17 | N/A | Tyvaso® (treprostinil solution for inhalation) | 9,339,507 |
| Omeros Corp. v. Lupin Ltd., 17-0803 (D. Del.) | 22-Jun-17 | Hon. Richard G. Andrews | Omidria® (phenylephrine / ketorolac for injection) | 8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Omeros Corp. v. Lupin Ltd., 17-4595 (D.N.J.) | 22-Jun-17 | Hon. Brian R. Martinotti | Omidria® (phenylephrine / ketorolac for injection) | 8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Aurobindo Pharma USA Inc. v. Andrx Corp., IPR2017-01648 (PTAB) | 22-Jun-17 | N/A | Fortamet® (metformin HCl extended-release tablets) Actoplus® Met XR (metformin HCl / pioglitazone HCl extended-release tablets) | 6,866,866 |
| Teijin Ltd. v. Indoco Remedies Ltd., 17-0809 (D. Del.) | 23-Jun-17 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) | 7,361,676 8,372,872 9,107,912 |
| Bayer Intellectual Property GMBH v. Invagen Pharms., Inc., 17-0812 (D. Del.) | 23-Jun-17 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Amgen Inc. v. Alkem Labs. Ltd., 17-0815 (D. Del.) | 23-Jun-17 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Lupin Ltd., 17-0816 (D. Del.) | 23-Jun-17 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Macleods Pharms., Ltd., 17-0817 (D. Del.) | 23-Jun-17 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Aurobindo Pharma USA Inc. v. Andrx Corp., IPR2017-01673 (PTAB) | 23-Jun-17 | N/A | Fortamet® (metformin HCl extended-release tablets) Actoplus® Met XR (metformin HCl / pioglitazone HCl extended-release tablets) | 6,790,459 |
| Biogen Int’l GMBH v. Amneal Pharms. LLC, 17-0823 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 7,619,001 7,803,840 8,399,514 |
| Biogen Int’l GMBH v. Aurobindo Pharma U.S.A., Inc., 17-0824 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Hetero USA Inc., 17-0825 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen MA Inc. v. Impax Labs., Inc., 17-0826 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Prinston Pharm. Inc., 17-0827 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Slayback Pharma LLC, 17-0828 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen Int’l GMBH v. Teva Pharms. USA, Inc., 17-0829 (D. Del.) | 26-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Concert Pharms., Inc. v. Incyte Corp., PGR2017-00034 (PTAB) | 27-Jun-17 | N/A | Jakafi® (ruxolitinib phosphate tablets) | 9,662,335 |
| Biogen MA Inc. v. MSN Labs. Private Ltd, 17-0845 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Graviti Pharms Pvt. Ltd, 17-0846 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Shilpa Medicare Ltd., 17-0847 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Sun Pharma Global FZE, 17-0848 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen MA Inc. v. Windlas Healthcare, Pvt. Ltd., 17-0849 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Biogen Int’l GMBH v. Alkem Labs. Ltd., 17-0850 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Cipla Ltd., 17-0851 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Glenmark Pharms. Ltd., 17-0852 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Lupin Atlantis Holdings SA, 17-0853 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Torrent Pharms. Ltd., 17-0854 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Pharmathen S.A., 17-0855 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. TWi Pharms., Inc., 17-0856 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Macleods Pharms., Ltd., 17-0857 (D. Del.) | 28-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Sebela Int’l Ltd. v. Actavis Labs. FL, Inc., 17-4789 (D.N.J.) | 28-Jun-17 | Hon. Claire C. Cecchi | Brisdelle® (paroxetine capsules) | 9,393,237 |
| Biogen Int’l GMBH v. Stason Pharms., Inc., 17-1133 (C.D. Cal.) | 30-Jun-17 | Hon. Douglas F. McCormick | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. Sandoz Inc., 17-1606 (D. Col.) | 30-Jun-17 | Hon. Michael E. Hegarty | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Forest Labs., LLC v. Sun Pharma Global FZE, 17-0865 (D. Del.) | 30-Jun-17 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 8,933,030 |
| Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 17-0867 (D. Del.) | 30-Jun-17 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 5,665,772 |
| Biogen Int’l GMBH v. Accord Healthcare Inc., 17-0872 (D. Del.) | 30-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Par Pharm., Inc., 17-0873 (D. Del.) | 30-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Sandoz Inc., 17-0874 (D. Del.) | 30-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Sawai USA, Inc., 17-0875 (D. Del.) | 30-Jun-17 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. Accord Healthcare Inc., 17-0612 (M.D.N.C.) | 30-Jun-17 | Hon. William L. Osteen, Jr. | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Zydus Pharms. (USA) Inc., 17-4857 (D.N.J.) | 30-Jun-17 | Hon. Brian R. Martinotti | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Par Pharm., Inc., 17-4984 (S.D.N.Y.) | 30-Jun-17 | Hon. Jesse M. Furman | Tecfidera® (dimethyl fumarate delayed-release capsules) | 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Mylan Pharms. Inc., 17-0116 (N.D.W.V.) | 30-Jun-17 | Hon. Irene M. Keeley | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
GENERICally Speaking Summer 2017
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.